See also this year's filing and all EDGAR filings for this company.
PDF Report 0001755237_2022_Cyclerion_Therapeutics_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.030710239651416123, 'aggregate_val': 59137000, 'exp_sum': 57375000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 20620000, 'ResearchAndDevelopmentExpense': 37636000, 'remainder_Expenses': -881000}} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100020 - Statement - Consolidated and Combined Statements of Operations and Comprehensive Loss 2': 2, '100040 - Statement - Consolidated and Combined Statements of Operations and Comprehensive Loss': 13}} |
Graph
Absolute values for 0001755237, Cyclerion Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 55,457,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 65,000 |
| 3 | remainder_Assets | 3,809,000 |
| 4 | LiabilitiesCurrent | 11,085,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 20,620,000 |
| 9 | ResearchAndDevelopmentExpense | 37,636,000 |
| 10 | remainder_Expenses | 881,000 |
| 11 | remainder_Revenues | 3,942,000 |
| 12 | remainder_NetIncome | 3,548,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 59,331,000 |
| 1 | Liabilities | 11,085,000 |
| 2 | Expenses | 59,137,000 |
| 3 | Revenues | 3,942,000 |
| 4 | StockholdersEquity | 48,246,000 |
| 5 | NetIncome | -51,647,000 |
| 6 | ComprehensiveNetIncome | -51,647,000 |
| 7 | BaseVar | 68,521,500 |
| 8 | EconomicCapitalRatio | 0.890 |
Edgar->Model Mapping
Feature Distribution
Change over Time
